concentrate for solution for infusion
Sponsors
Alexion Pharmaceuticals Inc., AstraZeneca AB
Conditions
Lupus Nephritis (LN)
Immunoglobulin A Nephropathy (IgAN)unresectable pleural or peritoneal malignant mesothelioma
Phase 2
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
CompletedCTIS2023-507977-16-00
Start: 2021-05-10End: 2025-07-15Target: 87Updated: 2025-06-04
A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma
RecruitingCTIS2024-511841-20-00
Start: 2013-09-23Target: 1Updated: 2025-01-24